标题
Carfilzomib
作者
关键词
-
出版物
BLOOD
Volume 121, Issue 6, Pages 893-897
出版商
American Society of Hematology
发表日期
2013-02-08
DOI
10.1182/blood-2012-10-459883
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
- (2012) Ravi Vij et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
- (2012) M. Alsina et al. CLINICAL CANCER RESEARCH
- Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib
- (2011) Anne C. Mirabella et al. CHEMISTRY & BIOLOGY
- Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
- (2011) D. J. Kuhn et al. CURRENT CANCER DRUG TARGETS
- Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
- (2011) J. Yang et al. DRUG METABOLISM AND DISPOSITION
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- p21WAF1/CIP1 Upregulation through the Stress Granule-Associated Protein CUGBP1 Confers Resistance to Bortezomib-Mediated Apoptosis
- (2011) Cristina Gareau et al. PLoS One
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
- (2010) S. Bringhen et al. BLOOD
- PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
- (2010) Ajita V. Singh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study
- (2010) Karthik Venkatakrishnan et al. CLINICAL THERAPEUTICS
- Proteostenosis and plasma cell pathophysiology
- (2010) Simone Cenci et al. CURRENT OPINION IN CELL BIOLOGY
- Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
- (2010) M Ri et al. LEUKEMIA
- Characterization of bortezomib-adapted I-45 mesothelioma cells
- (2010) Lidong Zhang et al. Molecular Cancer
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
- (2009) Matthew Britton et al. CHEMISTRY & BIOLOGY
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
- (2009) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
- (2009) D Gutman et al. LEUKEMIA
- Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells
- (2009) T Rückrich et al. LEUKEMIA
- Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
- (2008) Deborah J. Kuhn et al. BLOOD
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer
- (2008) Bruce D. Dorsey et al. JOURNAL OF MEDICINAL CHEMISTRY
- Point Mutation of the Proteasome 5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line
- (2008) S. Lu et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Histone H2A Monoubiquitination Represses Transcription by Inhibiting RNA Polymerase II Transcriptional Elongation
- (2008) Wenlai Zhou et al. MOLECULAR CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started